T2‐low severe asthma clinical spectrum and impact: The Greek PHOLLOW cross‐sectional study
Clinical and Translational Allergy · 2025-02 · 15 (2)
DOI: 10.1002/clt2.70035 ↗Abstract
Abstract Background Data on type 2 (T2)‐low severe asthma (SA) frequency is scarce, resulting in an undefined unmet therapeutic need in this patient population. Our objective was to assess the frequency and characterize the profile and burden of T2‐low SA in Greece. Methods PHOLLOW was a cross‐sectional study of adult SA patients. Based on a novel proposed classification system, patients were classified as T2‐low if blood eosinophil count (BEC; cells/μL) was
EUVIMED